SHIM
AARD

Stone House Investment Management’s Aardvark Therapeutics AARD Stock Holding History

Stone House Investment Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.77K Hold
1,000
– – ﹤0.01% 503
2025
Q4 		$13.1K Hold
1,000
– – ﹤0.01% 296
2025
Q3 		$13.3K Buy
+1,000
New +$11.3K ﹤0.01% 261

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Stone House Investment Management's AARD Position: Q1 2026 in Review

Stone House Investment Management held its Aardvark Therapeutics (AARD) position steady in Q1 2026 at 1,000 shares worth $3.77K. The position accounts for ﹤0.01% of the portfolio, ranked #503.

Stone House Investment Management first reported a position in AARD in Q3 2025 and has held it in 3 quarters since. The position peaked at $13.3K in Q3 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Stone House Investment Management held 1,000 shares of Aardvark Therapeutics worth $3.77K as of Q1 2026.
  • Stone House Investment Management left its Aardvark Therapeutics share count unchanged in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #503 holding.
  • Stone House Investment Management first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Stone House Investment Management's Aardvark Therapeutics position peaked at $13.3K in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.